Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 6.53% and Operating profit at -43.06% over the last 5 years
2
The company has declared positive results in Mar'2025 after 7 consecutive negative quarters
3
With ROE of 1.54%, it has a fair valuation with a 3.55 Price to Book Value
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,991 Million (Mid Cap)
230.00
NA
0.00%
-0.50
2.02%
2.85
Revenue and Profits:
Net Sales:
94 Million
(Quarterly Results - Sep 2025)
Net Profit:
12 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.64%
0%
-3.64%
6 Months
-7.53%
0%
-7.53%
1 Year
15.2%
0%
15.2%
2 Years
13.17%
0%
13.17%
3 Years
-41.07%
0%
-41.07%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Shanghai OPM Biosciences Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.53%
EBIT Growth (5y)
-43.06%
EBIT to Interest (avg)
31.48
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.56
Sales to Capital Employed (avg)
0.13
Tax Ratio
57.18%
Dividend Payout Ratio
227.20%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.48%
ROE (avg)
4.90%
Valuation key factors
Factor
Value
P/E Ratio
230
Industry P/E
Price to Book Value
3.55
EV to EBIT
386.63
EV to EBITDA
83.26
EV to Capital Employed
8.42
EV to Sales
18.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
2.18%
ROE (Latest)
1.54%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
93.80
94.10
-0.32%
Operating Profit (PBDIT) excl Other Income
10.90
28.00
-61.07%
Interest
0.70
0.80
-12.50%
Exceptional Items
-1.60
1.30
-223.08%
Consolidate Net Profit
11.80
22.70
-48.02%
Operating Profit Margin (Excl OI)
116.20%
142.30%
-2.61%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -0.32% vs 12.43% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is -48.02% vs 55.48% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
295.70
243.00
21.69%
Operating Profit (PBDIT) excl Other Income
54.60
61.70
-11.51%
Interest
3.20
3.30
-3.03%
Exceptional Items
4.60
1.50
206.67%
Consolidate Net Profit
20.20
53.30
-62.10%
Operating Profit Margin (Excl OI)
-3.20%
78.00%
-8.12%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 21.69% vs -17.23% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -62.10% vs -49.43% in Dec 2023
About Shanghai OPM Biosciences Co. Ltd. 
Shanghai OPM Biosciences Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






